Thank you for submitting your manuscript entitled 'β-arrestin-1 mediates the TCR-triggered rerouting of distal receptors to the immunological synapse'. I have now received the three reports on your paper.
As you can see below, all three referees appreciate your data and conclusions. However, further amendments and additional experiments are needed to support your data and claims. I would like to focus your attention specifically to address the PKC-mediated phosphorylation of β-arrestin-1 by trying to identify the phosphorylated sites and to show that this phosphorylation is direct and pivotal for TCR regulation. Based on amendments that constructively address the concerns, I would like to invite you to submit a revised version of the manuscript. I should also add that it is EMBO Journal policy to allow only a single round of revision and that it is therefore important to address all concerns raised at this stage. Please do not hesitate to contact me in case of further questions or to outline the timeframe for necessary experimental work. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
------------------------------------------------REFEREE COMMENTS

Referee #1
The authors explore molecular mechanisms that ensure prolong signaling of T cell receptors (TCRs) at the immunological synapse that T cells from with antigen-presenting cells. The authors describe several novel findings. First, they show that b-arrestin1 (but not closely related b-arrestin2) directly binds immunoreceptor tyrosine-based activation motifs (ITAMs), with the preference for ITAMs without phosphorylated tyrosines. Second, they present strong evidence (although do not definitively prove) that b-arrestin1 is phosphorylated by PKC activated by engaged TCRs. Finally, the authors show that b-arrestin1 is involved in the internalization of non-engaged TCRs in response to PKC activation by engaged TCRs, and routing of fresh TCRs to the immunological synapse, which is necessary for sustained signaling. The authors should be commended for testing proposed interaction with purified b-arr1, as well as for elegant experiments with cells expressing two transgenic TCRs with different specificity. Overall, the manuscript describes novel b-arrestin function playing important role in T cell activation and immune response. However, several issues regarding data presentation and discussion should be addressed.
1. Fig. 2A . Polar core in all arrestins is a three-dimensional arrangement, involving residues that are scattered all over linear sequence (Cell. 1999 Apr 16; 97(2):257-69; Structure. 2001 Sep; 9(9) :869-80). 2. Fig. 3D . The level of b-arr1 protein knockdown should be quantified and shown, with statistical significance indicated (in a bar graph, like the level of its mRNA, which is less relevant, is shown). 3. Fig. 4G . Which blot represents the level of PKC phosphorylation? This should be clearly labeled. If that's the top blot, the authors should explain an increase in phosphorylation at 30 min with PKC inhibitor. 4. Figs. 6,7. The level of b-arrestin knockdown achieved with shRNA in the experiments in each cell type should be shown in both figures. One cannot just assume that knockdown efficiency was the same as in Fig. 3D , as the effects of shRNA (and siRNA, for that matter) vary a lot in different cell types. 5. Sequence alignment of residues 319-382 of b-arrestins 1 and 2 (preferably from several species) might suggest which residues are likely critical for ITAM binding. This alignment should be shown in the supplement, unless the authors choose to test the role of particular residues by mutagenesis followed by a pull-down with GST fusion (as described for WT b-arrestin1 element on pp. 7-8). In that case the results should be shown in the main paper. 6. Since ITAM-binding elements are constitutively exposed in b-arr1(319-418) fragment, but not in full-length b-arr1 (p. 8), crystal structure of b-arr1 (Structure. 2001 Sep; 9(9) :869-80) might also suggest which parts of this sequence are important. 7. The authors should show (in the supplement) putative PKC sites on b-arrestin1 and compare these sequences to b-arrestin2. This analysis might identify relatively few suspects playing a role in the described phenomena. Moreover, the authors can exclude elements that are not accessible on the surface of either b-arrestin, as both crystal structures are available (Structure. 2001 Sep; 9(9):869-80; J Mol Biol. 2011 Feb 25; 406(3) :467-78). 8. Two systems of arrestin names are currently in use: b-arrestin1 and b-arrestin2, a.k.a. arrestin-2 and arrestin-3. The authors should provide a translation from the system they use to the other.
Referee #2
This manuscript reports a novel interaction between T cell receptors (TCRs) and beta-arrestin1. The authors also demonstrate that beta-arrestin1 is necessary for down-regulation of bystander TCRs and mediates cross-talk between TCRs and G protein-coupled receptors such as the chemokine receptor CXCR4. These findings are interesting because they suggest a previously-unappreciated role for arrestins in regulating the immunological synapse and furthermore provide mechanistic insight into poorly-understood aspects of TCR regulation. Specific comments are as follows:
1. In general, the studies reported here seem rigorously performed and the data are compelling. One weak link, though, is the evidence that PKC can directly phosphorylate beta-arrestin1. This is a significant part of the story, since the authors claim that direct PKC phosphorylation of betaarrestin1 accounts for previously-unexplained PKC-mediated regulation of TCRs. Fig. 4G shows anti-phosphoserine Western blots of immunoprecipitated beta-arrestin1 at different time points of TCR stimulation. However, the increase in apparent phosphoserine labeling is quite modest, no quantification was performed, no evidence for the specificity of the anti-phosphoserine antibody is offered, and this key experiment was apparently only done twice. Moreover, the amount of betaarrestin1 immunoprecipitated (bottom blot) does not appear to be equal between the samples; lane 1 looks low in terms of immunoprecipitated beta-arrestin1, so if the anti-phosphoserine blot at the top of the panel was normalized to total beta-arrestin1, there probably would be no significant effect of stimulation. Finally, the authors state that the PKC inhibitor Go6976 blocked stimulation-induced beta-arrestin1 phosphorylation, but if you compare the 30-minute time points in Fig. 4G , it looks as though the PKC inhibitor had little or no effect on apparent phosphoserine labeling. In Fig. 4H , which is also unquantified and based on only two experiments, the authors performed in vitro phosphorylation of beta-arrestin1 with purified PKC. However, PKC is a notoriously promiscuous kinase when added in large amounts as a purified enzyme to protein preps in vitro, and most any protein can be phosphorylated by PKC in vitro under such conditions. For example, an early & rigorous study on beta-arrestin1 phosphorylation by the Lefkowitz group (Lin et al., J. Biol. Chem., 1999) showed that, indeed, purified PKC could phosphorylate beta-arrestin1 in vitro, but 2-D phosphoamino acid gel analysis revealed that the pattern of phosphorylation induced on betaarrestin1 by purified PKC looked nothing like the pattern of phosphorylation observed for betaarrestin1 from cells. Thus, neither Figures 4G or 4H offer convincing evidence that PKC can directly phosphorylate beta-arrestin1 in a cellular context. This aspect of the story needs to be better developed. If the authors can't prove the specificity of their anti-phosphoserine antibody, they should perform 32P labeling studies to assess beta-arrestin1 phosphorylation state. Two-dimensional gel electrophoresis studies could be performed to demonstrate that the pattern of phosphorylation mediated by PKC in vitro is similar to the pattern of beta-arrestin1 phosphorylation observed in cells. The experiments illustrated in Figure 4G & 4H, or experiments like them, should be performed more than just twice and the data should be rigorously quantified. Ideally, the site(s) of PKC phosphorylation on beta-arrestin1 should be identified, as it would be truly convincing if mutation of the PKC phosphorylation site(s) on beta-arrestin1 led to altered TCR regulation, as would be predicted by the authors' model. 2. None of the Western blots shown in this manuscript contain molecular mass markers. Granted, a few of the blots are closely cropped for space reasons, but for those blots that are no closely cropped, molecular mass markers should be shown in order to reveal the apparent molecular masses of the various proteins being studied.
Referee #3
This is an interesting and important study by Alarcon and colleagues demonstrating a novel role for b-arrestin 1 in TCR internalization and function. The studies are well performed and support a working model ( figure 7E ) and advances our ability to dissect the molecular cascade of events in the functions of the immunological synapse. The ability of b-arrestin 1 to interact with the distal receptors in IS formation provides a novel molecular mechanism. I have a few minor issues that the authors should be able to address-1. The author should provide a resolution of two experimental observations. Since b-arrestin 1 interacts with non-phosphorylated zeta-a and not with doubly phosphorylated zeta-a peptides (figures 1B and1D), how might b-arrestin 1 increase its association with the TCR complex following TCR engagement ( Figure 1C) ? Does the interaction with b-arrestin occur within an endosomal compartment where zeta is now de-phosphorylated to enable interaction or is there a different mechanism involved? 2. Figure 2 -While the authors have demonstrated that b-arr1 (319-382) is sufficient to interact with CD3zeta, might there also be other domains within b-arr1 (1-319) that might also mediate a CD3zeta interaction. The authors should test the predicted negative control that b-arr 1 (1-319) does not interact with CD3zeta.
3. Figure 3D -What is the effect of sh-b-Arr-1 on basal surface TCR expression? If there is a basal effect, how might this affect the major conclusions of this study.
1st Revision -authors' response 18 November 2013
Referee #1
We thank the referee for the positive comments on the manuscript and recommendations to improve it.
1. Fig. 2A . Polar core in all arrestins is a three-dimensional arrangement, involving residues that are scattered all over linear sequence (Cell. 1999 Apr 16; 97(2):257-69; Structure. 2001 Sep; 9(9):869-80) .
We thank the referee for the clarification. We have removed from Fig. 2A any mention to the position of polar core residues.
Fig. 3D. The level of b-arr1 protein knockdown should be quantified and shown, with statistical significance indicated (in a bar graph, like the level of its mRNA, which is less relevant, is shown).
We have performed this quantification which is now shown in Fig. 3D of the revised manuscript.
Fig. 4G. Which blot represents the level of PKC phosphorylation? This should be clearly labeled. If that's the top blot, the authors should explain an increase in phosphorylation at 30 min with PKC inhibitor.
The result is now Fig. 5A . We have indicated that the band recognized by the antibody to phosphorylated PKC substrates is phospho-ß-arr1. After densitometry, the intensity of this band appears always, even at 30 min, lower than in the untreated sample. We have mentioned this in the Text. Fig. 3D , as the effects of shRNA (and siRNA, for that matter) vary a lot in different cell types.
Figs. 6,7. The level of b-arrestin knockdown achieved with shRNA in the experiments in each cell type should be shown in both figures. One cannot just assume that knockdown efficiency was the same as in
We now show -ß-arr1 protein expression after knockdown in 2B4 cells (Fig. 3D ) and in double transgenic OT-1+HY+ T cells (Fig. 4E) .
Sequence alignment of residues 319-382 of b-arrestins 1 and 2 (preferably from several species) might suggest which residues are likely critical for ITAM binding. This alignment should be shown in the supplement, unless the authors choose to test the role of particular residues by mutagenesis followed by a pull-down with GST fusion (as described for WT b-arrestin1 element on pp. 7-8). In that case the results should be shown in the main paper.
We have now included as Suppl. Fig. S2 an alignment of -ß-arr1 and -ß-arr2 in different mammalian species to show that there are conserved sequences present in the first protein that are absent in the second and that thereby could be important for ITAM binding. We believe however that the detailed characterization of the involved amino acid residues should be left for a follow-up study, since the present one is already quite extensive. (Structure. 2001 Sep; 9(9):869-80; J Mol Biol. 2011 Feb 25; 406(3):467-78) .
Since ITAM-binding elements are constitutively exposed in b-arr1(319-418) fragment, but not in
We have now identified a unique site in ß-arr1 that becomes phosphorylated by PKC (Fig. 5 ). This site, Ser163, and surrounding residues are conserved in ß-arr2. Therefore, rather than based on the susceptibility to phosphorylation by PKC we believe the differential binding to the ITAM is based on differences in the 319-382 region.
Two systems of arrestin names are currently in use: b-arrestin1 and b-arrestin2, a.k.a. arrestin-2 and arrestin-3. The authors should provide a translation from the system they use to the other.
We have now mentioned the other nomenclature the first time both proteins are mentioned.
Referee #2
We thank the referee for the positive comments on the manuscript and recommendations to improve it. Fig. 4G , it looks as though the PKC inhibitor had little or no effect on apparent phosphoserine labeling.
We have now quantified the immunoblotting experiments with phospho-specific PKC substrate antibody and the result shows a clear induction of phosphorylation after TCR triggering in T cells not treated with the PKC inhibitor (new Fig. 5A) . Furthermore, these quantification shows that the phosphorylation signal in the presence of the inhibitor is always, even at 30 min, below the untreated control.
In Fig. 4H We thank the referee for this comment, which we have followed in full to identify PKC phosphorylation sites in ß-arr1. We have used phosphoproteomic techniques on samples generated in vitro and in vivo and have demonstrated that PKC phosphorylates Ser163 of ß-arr1 in a TCR triggering-dependent manner. We have also studied the effect of the S163A mutation on the association of in ß-arr1 to the TCR and on ß-arr1 phosphorylation (identified with the phosphorspecific PKC substrate antibody). The results are shown in Fig. 5 , Suppl. Fig. S4 and Suppl. Fig. S5 . We consider that these experiments quite convincingly demonstrate that ß-arr1 is phosphorylated by PKC in T cells. We have now indicated the position of the most relevant molecular mass markers in all western blots.
None of the Western blots shown in this manuscript
Referee #3
The author should provide a resolution of two experimental observations. Since b-arrestin 1 interacts with non-phosphorylated zeta-a and not with doubly phosphorylated zeta-a peptides (figures 1B and1D), how might b-arrestin 1 increase its association with the TCR complex following TCR engagement (Figure 1C)? Does the interaction with b-arrestin occur within an endosomal compartment where zeta is now de-phosphorylated to enable interaction or is there a different mechanism involved?
T cell stimulation with antigen or even anti-CD3 antibodies never induces the phosphorylation of all tyrosines in the ITAMs of all the TCRs. When antigen-loaded APCs are used for stimulation it is clear that not all TCRs can be simultaneously contacted at the immunological synapse since only a small fraction of the T cell plasma membrane is in contact with the APC. But even when using anti-CD3 antibodies in saturating conditions (such as those used in Fig. 1C ) most of the CD3zeta ITAMs do not become phosphorylated. For instance, immunoblotting with anti-phosphotyrosine antibody reveals bands corresponding to phospho-zeta that are barely visible with an antibody against total zeta (e.g. Sahuquillo et al (1998 ) JEM 187: 1179 -1182 . In addition, old data from the laboratories of R. Germain, N. van Oers, P. Love and others show that even in optimal conditions CD3zeta is never completely found in the fully phosphorylated p23 form. A majority is in forms of partial phosphorylation p21 and p18. Finally, phosphorylation of the ITAMs of CD3zeta is more easily detectable than the phosphorylation of the ITAM of CD3epsilon. Phosphorylation of the ITAMs of CD3gamma and CD3delta is basically undetectable. In summary, of the total content of ITAMs in all the TCRs of a T cell a major fraction will not be phosphorylated and therefore will be available for ß-arr1 binding.
Figure 2-While the authors have demonstrated that b-arr1 (319-382) is sufficient to interact with
CD3zeta, might there also be other domains within b-arr1 (1-319) that might also mediate a provides many molecular details of TCR regulation by b-arrestin1. The manuscript was greatly improved in revision. The identification of PKC site in b-arestin1 and demonstration that point mutant Ser163Ala is inactive strongly supports authors' model. The data also suggest an unexpected alternative way of b-arrestin activation, via direct phosphorylation within the phosphate sensor, rather than by the binding to it of the phosphates attached by GRKs to a GPCR.
Minor editing in a few places can further improve the text: p. 7, top line, "preferably" should be "preferentially"; p. 8, last line, "could not be claimed on reduced" should be "could not be attributed to reduced" or "could not be explained by reduced".
Additional correspondence (author) 08 December 2013
I am enclosing a new version of the Text with the changes suggested by the reviewer already introduced. We have also gone again through the Text to correct possible typos. I have not highlighted the changes; they are minor. We have modified Figure 5C (I am enclosing the PDF) because going through our proteomics data we realized that the coverage of the protein that we had was much higher than originally thought. It is 72%. This is adds further strength to the idea that the only phosphorylated peptide is this containing Ser163. I have taken the liberty of doing this modification. I am finally, enclosing 5 bullet points and PDFs of the scanned unprocessed blots (1 PDF per Figure) . Thank you very much!.
